SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Grigoriadis Dimitri E. (Last) (First) (Middle) NEUROCRINE BIOSCIENCES, INC. 12790 EL CAMINO REAL (Street) SAN DIEGO CA 92130 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/10/2008	3. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [ NBIX ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Vice President, Research	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,358	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)(1)	09/19/1998	08/19/2008	Common Stock	7,500	6.5	D
Employee Stock Option (right to buy)(2)	07/01/1999	06/01/2009	Common Stock	4,000	4.875	D
Employee Stock Option (right to buy)(3)	09/26/2007	07/23/2013	Common Stock	937	10.9	D
Employee Stock Option (right to buy)(3)	09/26/2007	09/26/2013	Common Stock	4,737	10.9	D
Employee Stock Option (right to buy)(3)	09/26/2007	06/22/2010	Common Stock	3,750	10.9	D
Employee Stock Option (right to buy)(3)	09/26/2007	06/26/2011	Common Stock	3,125	10.9	D
Employee Stock Option (right to buy)(3)	09/26/2007	07/05/2012	Common Stock	3,250	10.9	D
Employee Stock Option (right to buy)(3)	09/26/2007	09/05/2012	Common Stock	10,125	10.9	D
Restricted Stock Units	(4)	(4)	Common Stock	16,667	(5)	D
Restricted Stock Units	(6)	(6)	Common Stock	10,000	(5)	D

Explanation of Responses:

1. Represents option of which one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable on September 19, 1998 and an additional one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable each month thereafter.

2. Represents option of which one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable on July 1, 1999 and an additional one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable each month thereafter.

3. This option is exercisable in three annual installments. The first installment became exercisable on September 26, 2007, and the next two installments become exercisable on September 26, 2008 and September 26, 2009.

4. The restricted stock units vest in three annual installments. The first installment became exercisable on October 26, 2007, and the next two installments become exercisable on September 26, 2008 and September 26, 2009.

5. Each restricted stock unit represents a contingent right to receive one share of NBIX common stock.

6. The restricted stock units vest in three annual installments beginning February 3, 2008 and the next two installments become exercisable on January 3, 2009 and January 3, 2010.

Remarks:

	Margaret E. Valeur-Jensen, By Power of Attorney	01/17/2008
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY - SECURITIES LAW COMPLIANCE

The undersigned, as an Officer of Neurocrine Biosciences, Inc. (the "Corporation"), hereby constitutes and appoints,

jointly and severally Kevin C. Gorman, Margaret E. ValeurJensen and Timothy P. Coughlin, hereby and each of them,

the undersigned's true and lawful attorney-in-fact and agent, each with the power of substitution for him in any

and all capacities to complete and execute such Forms 144, advisable pursuant to Rule 144 promulgated under the

Securities Act of 1933 (as amended) and Forms 3, 4, and 5 advisable pursuant to section 16 of the Securities

Exchange Act of 1934, and other forms as such attorney shall in his or her discretion determine to be required by

the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the

undersigned's ownership, acquisition or disposition of securities of the Corporation, and to do all acts necessary

in order to file such forms with the Securities and Exchange Commission, any securities exchange or national

association, the Corporation and such other person or agency as the attorney shall deem appropriate. The undersigned

hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue

hereof.



This Limited Power of Attorney is executed at San Diego, California, as of the date set forth below.



(Signature)



Dimitri Grigoriadis



Date: 1/10/08